Supplements That Help With Wegovy Diarrhea: What the Evidence Actually Shows

How common is Wegovy diarrhea, and how bad is it?

In the Wegovy label's pooled trials — 2,116 adults on semaglutide 2.4 mg weekly and 1,261 on placebo, up to 68 weeks — diarrhea was reported by 30% versus 16%, second only to nausea at 44% [1]. Diarrhea was the reason 0.7% of people on Wegovy stopped treatment versus 0.1% on placebo, and 6.8% stopped for any adverse reaction versus 3.2% [1].

The label also carries a warning for severe gastrointestinal reactions, which occurred in 4.1% of Wegovy-treated adults versus 0.9% on placebo [1].

Is any supplement proven for Wegovy diarrhea?

No. We found no published trial that tested any supplement, probiotic or fiber product in people taking semaglutide. The trials below studied antibiotic-associated diarrhea, acute infectious diarrhea in children, and diarrhea-predominant IBS after an infection [2][3][4]. None of them enrolled people taking a GLP-1 drug, so none shows what a supplement does for Wegovy diarrhea.

Saccharomyces boulardii: tested in antibiotic-associated diarrhea

A meta-analysis of 21 randomized trials with 4,780 participants found that S. boulardii lowered the risk of antibiotic-associated diarrhea from 18.7% to 8.5% (risk ratio 0.47, 95% CI 0.38 to 0.57; number needed to treat 10) [2]. In the 15 adult trials (3,114 participants), the risk fell from 17.4% to 8.2% (risk ratio 0.49, 95% CI 0.38 to 0.63) [2]. An earlier review of 27 randomized trials in adults (5,029 patients) reported a similar pooled risk ratio of 0.47 (95% CI 0.35 to 0.63) for preventing antibiotic-associated diarrhea, and found S. boulardii efficacious and safe in 84% of its placebo-controlled treatment arms [5].

The trials tested different products and doses, and none of them establishes a dose for diarrhea during Wegovy treatment.

Other probiotics: mixed results outside GLP-1 use

A Cochrane review of probiotics for acute infectious diarrhea included 82 studies with 12,127 participants, 11,526 of them children [6]. The authors reported marked statistical heterogeneity and evidence of publication bias, and no difference in the main outcomes among trials at low risk of bias on all indices [6]. In hospitalized adults starting antibiotics, a meta-analysis of 19 studies with 6,261 patients found C. difficile infection in 1.6% of probiotic users versus 3.9% of controls (risk ratio 0.42, 95% CI 0.30 to 0.57) [7].

Zinc: studied in children with infectious diarrhea

The Cochrane review of oral zinc included 33 trials with 10,841 children aged one month to five years, most done in Asian countries with a high risk of zinc deficiency [3]. In children older than six months, zinc may shorten the average duration of diarrhea by about half a day (mean difference −11.46 hours, 95% CI −19.72 to −3.19; 9 trials, 2,581 children, low-certainty evidence) and probably reduces the number still having diarrhea at day 7 (risk ratio 0.73, 95% CI 0.61 to 0.88) [3]. The review found not enough evidence to say whether zinc reduces death or hospitalization (very low certainty) [3]. It notes that WHO and UNICEF currently recommend zinc during acute diarrhea in children [3].

L-glutamine: one positive trial, in post-infectious IBS

In an 8-week double-blind trial, adults with diarrhea-predominant IBS after an enteric infection and increased intestinal permeability took glutamine 5 g three times daily or placebo; 54 glutamine and 52 placebo participants completed the study [4]. In this trial of adults with post-infectious IBS, 79.6% of those taking glutamine and 5.8% of those taking placebo met the study's primary improvement measure, a drop of at least 50 points on the IBS severity score [4]. The authors also reported that elevated urinary lactulose/mannitol ratios normalized in the glutamine group but not in the placebo group [4]. Adverse events and discontinuations were low and similar in both groups [4].

Psyllium and other over-the-counter options

We found no trial of psyllium or any other fiber product in people taking semaglutide. Peppermint oil has trial support in IBS: a meta-analysis of 9 trials with 726 patients found it superior to placebo for overall symptom improvement and for abdominal pain, with heartburn the most common adverse effect — but the outcomes reported were symptoms and adverse events, not stool frequency [8].

What the Wegovy label tells you to watch for

The label lists acute kidney injury due to volume depletion as a warning and says renal function should be monitored in patients reporting adverse reactions that could lead to volume depletion [1]. In the Wegovy trials, kidney injury occurred at 0.4 versus 0.2 cases per 100 patient-years, more often during dose titration and often after gastrointestinal fluid loss [1].

The label warns that use has been associated with severe gastrointestinal adverse reactions and says Wegovy is not recommended in patients with severe gastroparesis [1]. Postmarketing reports listed in the semaglutide labels include ileus, intestinal obstruction and severe constipation with fecal impaction [1].

Wegovy delays gastric emptying and may affect the absorption of oral medicines [1]. The label reports that levothyroxine exposure increased 33% with semaglutide tablets, and advises monitoring oral medicines given alongside Wegovy, particularly those with a narrow therapeutic index or that require clinical monitoring [1].